Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

Related Citations for PubMed (Select 23456774)

1.

Top practice-changing articles over the last two years.

Kaatz S, Gage BF.

J Thromb Thrombolysis. 2013 Apr;35(3):325-32. doi: 10.1007/s11239-013-0896-x. Review.

PMID:
23456774
2.

Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm?

ElBardissi AW, DiBardino DJ, Chen FY, Yamashita MH, Cohn LH.

J Thorac Cardiovasc Surg. 2010 May;139(5):1137-45. doi: 10.1016/j.jtcvs.2009.10.064. Epub 2010 Mar 19.

PMID:
20303508
3.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
4.
5.

[Bleeding risk and perioperative management of patients anticoagulated with vitamin K antagnosists].

Angelo M, Stockner I, Wiedermann CJ.

Wien Med Wochenschr. 2008;158(21-22):615-20. doi: 10.1007/s10354-008-0610-3. Review. German.

PMID:
19052707
7.

Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.

Yates SW.

Hosp Pract (1995). 2011 Oct;39(4):7-16. doi: 10.3810/hp.2011.10.918. Review.

PMID:
22056819
8.

Prevention of stroke in patients with atrial fibrillation.

Olsson SB, Halperin JL.

Semin Vasc Med. 2005 Aug;5(3):285-92. Review.

PMID:
16123916
9.

Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database.

Brennan JM, Edwards FH, Zhao Y, O'Brien S, Booth ME, Dokholyan RS, Douglas PS, Peterson ED; DEcIDE AVR Research Team.

J Am Coll Cardiol. 2012 Sep 11;60(11):971-7. doi: 10.1016/j.jacc.2012.05.029. Epub 2012 Aug 22.

10.

Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.

Deedwania PC, Huang GW.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):265-75. doi: 10.2165/11592410-000000000-00000. Review.

PMID:
21740079
11.

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW.

J Am Coll Cardiol. 2013 Feb 12;61(6):651-8. doi: 10.1016/j.jacc.2012.09.057.

12.

The use of vitamin K in patients on anticoagulant therapy: a practical guide.

Hanslik T, Prinseau J.

Am J Cardiovasc Drugs. 2004;4(1):43-55. Review.

PMID:
14967065
13.

Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes.

Bloomfield HE, Krause A, Greer N, Taylor BC, MacDonald R, Rutks I, Reddy P, Wilt TJ.

Ann Intern Med. 2011 Apr 5;154(7):472-82. doi: 10.7326/0003-4819-154-7-201104050-00005.

PMID:
21464349
14.

Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.

Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M; RE-LY Investigators.

Circulation. 2012 Jul 17;126(3):343-8. doi: 10.1161/CIRCULATIONAHA.111.090464. Epub 2012 Jun 14. Erratum in: Circulation. 2012 Sep 4;126(10):e160. Heidbuchle, Hein [corrected to Heidbuchel, Hein].

15.

Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.

Lip GY, Piotrponikowski P, Andreotti F, Anker SD, Filippatos G, Homma S, Morais J, Pullicino P, Rasmussen LH, MarĂ­n F, Lane DA; Heart Failure Association (EHFA) of the European Society of Cardiology (ESC) and the ESC Working Group on Thrombosis.

Thromb Haemost. 2012 Dec;108(6):1009-22. doi: 10.1160/TH12-08-0578. Epub 2012 Oct 23.

PMID:
23093044
16.

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.

Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH.

Lancet. 2012 Nov 17;380(9855):1749-58. doi: 10.1016/S0140-6736(12)60986-6. Epub 2012 Oct 2. Erratum in: Lancet. 2013 Jan 19;381(9862):204.

PMID:
23036896
18.

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.

Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L; ARISTOTLE Investigators.

Am Heart J. 2010 Mar;159(3):331-9. doi: 10.1016/j.ahj.2009.07.035. Erratum in: Am Heart J. 2010 Jun;159(6):1162.

PMID:
20211292
19.
20.

Antiplatelet agents and anticoagulants for hypertension.

Lip GY, Felmeden DC, Dwivedi G.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD003186. doi: 10.1002/14651858.CD003186.pub3. Review.

PMID:
22161375
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk